ScripsAmerica Inc. (SCRCQ)

[Guts]

ScripsAmerica to secure distribution commitments for its RapiMed in China
PBR Staff Writer
Published 29 October 2013
ScripsAmerica has reported that its due diligence team will start formal distribution negotiations in November 2013 in preparation for the launch of its RapiMed children's pain reliever and fever reducer into the Chinese OTC market, valued at over $32bn.


In this regard, the company is planning to secure distribution commitments for its product across China, with its representatives conducting many meetings with hospitals, pharmacies, multi-level marketing companies and pharmaceutical sales networks.

ScripsAmerica CEO Bob Schneiderman said the company is confident that its upcoming ventures in China will produce strong sales revenue.

"ScripsAmerica believes RapiMed(R)'s ease of delivery and American-made quality assurance is the right product at the right time for the Chinese market," Schneiderman said.

The company will carry out pharmaceutical distribution meetings in the cities of Hong Kong, Chengdu, Yantai, Shenzhen and Beijing.

In addition, ScripsAmerica has already started to formally register RapiMed with the Chinese State Food and Drug Administration which will enable it to market and sell the product across the Chinese Market.